Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Am J Surg. 2008 Oct;196(4):505-11. doi: 10.1016/j.amjsurg.2008.06.023.

Improved breast cancer survival among hormone replacement therapy users is durable after 5 years of additional follow-up.

Author information

  • 1Division of Surgical Oncology, Department of Surgery, Portland, OR, USA.

Abstract

BACKGROUND:

We previously reported that breast cancer patients who used hormone replacement therapy (HRT) had significantly lower stage tumors and higher survival than never-users. We present an update with longer follow-up, HRT use data, and in vitro research.

METHODS:

Our database of 292 postmenopausal breast cancer patients was updated to include HRT type, duration, and disease status. In vitro effects of estrogen (E) and/or medroxyprogesterone (MPA) on breast cancer cell growth were measured.

RESULTS:

Tumor prognostic factors were better and survival rates higher for both E and combination HRT users of any duration. Use greater than 10 years correlated with node-negative disease, mammographically detected tumors, and 100% survival. E supported minimal proliferation; MPA induced cell death; E+MPA results were similar to E alone.

CONCLUSIONS:

HRT users, regardless of type or duration of HRT use, continued to have higher survival rates. In vitro results supported the clinical finding that outcomes for users of E and E+MPA were similar.

PMID:
18809052
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk